[Etravirine in first-line therapy].

Area of Science:

• Pharmacology
• Infectious Diseases
• Antiretroviral Therapy

Background:

• Etravirine (ETR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad in vitro activity against HIV-1.
• Limited data exist on ETR's role in first-line antiretroviral therapy (ART), despite increasing NNRTI resistance.
• Adverse effects are a primary reason for ART modification in initial treatment phases.

Purpose of the Study:

• To evaluate the role and suitability of etravirine in first-line ART.
• To assess ETR's safety and tolerability profile in initial treatment phases.
• To explore ETR's potential in patients with adherence issues or requiring treatment modification due to adverse effects.

Main Methods:

• Review of existing data on etravirine's efficacy, safety, and tolerability.
• Analysis of ETR's characteristics, including dosing, administration, and drug interactions.
• Consideration of ETR's genetic barrier and its role in second-line ART regimens.

Main Results:

• ETR demonstrates potency and efficacy, particularly in multi-treated patients.
• ETR exhibits a favorable safety profile with no central nervous system effects and good gastrointestinal, liver, and lipid safety.
• Rash is the most common adverse effect, similar to other NNRTIs.

Conclusions:

• ETR's safety and tolerability make it a viable option for ART modification due to adverse effects.
• ETR's once-daily dosing, water solubility, and lack of methadone interaction enhance its attractiveness for first-line therapy.
• ETR is particularly beneficial for patients with poor adherence, including intravenous drug users on methadone treatment.